Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00597818 · ClinicalTrials.gov registry record · Phase 2
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
A Phase 2 study, sponsored by Sucampo Pharma Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT00597818: Completed Phase 2 study, sponsored by Sucampo Pharma Americas.
NCT00597818 is a Phase 2 study that has completed, run by Sucampo Pharma Americas. The registered enrollment target is 121 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00597818, a Phase 2 study, has completed, sponsored by Sucampo Pharma Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
Interventions
- DRUG Placebo
- DRUG Cobiprostone
- DRUG Non-steroidal anti-inflammatory drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
What the finished NCT00597818 record still lists
NCT00597818 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00597818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00597818 about?
NCT00597818 is a clinical study titled "Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury". The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
What is the current status of trial NCT00597818?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2007-08. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00597818?
The interventions under investigation include: Placebo (DRUG), Cobiprostone (DRUG), Non-steroidal anti-inflammatory drug (DRUG).
Who is sponsoring clinical trial NCT00597818?
This trial is sponsored by Sucampo Pharma Americas, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00597818's enrollment target sits among peer trials
121 567th of 2000 higher than 1,432 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia